Affymetrix, Inc.
Ticker: AFFX 3380 Central Expressway
Exchange: NASDAQ-National Market Santa Clara, California 95051
Industry: Service (408) 522-6000

Type of Shares:Common Shares Filing Date:4/15/96
U.S. Shares:6,000,000 Offer Date:6/6/96
Non-U.S. Shares:0 Filing Range:$11.00 - $13.00
Primary Shares:6,000,000 Offer Price:$15.00
Secondary Shares:0 Gross Spread:$1.03
Offering Amount: $72,000,000 Selling:$0.61
Expenses:$800,000 Reallowance:$0.10
Shares Out After:22,239,231

ManagerTierPhone
Robertson, Stephens & CompanyLead Manager (415) 989-8500
CS First BostonCo-manager (212) 909-3312
Montgomery SecuritiesCo-manager 4156272220

Auditor: Ernst & Young
Audited
Income
Latest
Unaudited
Income
Prior
Unaudited
Income
Balance
Sheet
12/31/95 3/31/96 3/31/95 3/31/96
Revenue:$4.63$1.42$0.85Assets:$41.19
Net Income:-$10.75-$3.92-$2.17Liabilities:$6.53
EPS:-$0.61-$0.22-$0.12Equity:$34.65

Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year,
unaudited figures are partial year

Business Description
The company has developed and intends to establish its GeneChip system as the platform of choice for acquiring, analyzing and managing complex genetic information in order to improve the diagnosis, monitoring and treatment of disease. The company's system consists of disposable DNA probe arrays containing gene sequences on a chip, instruments to process the probe arrays, and software to analyze and manage genetic information. The company commenced commercial sales of the GeneChip system and an HIV probe array for research use in April 1996. The company manufactures its DNA probe arrays using an innovative and proprietary process that combines photolitho-graphic fabrication techniques from the semiconductor industry with solid phase DNA synthesis to assemble large amounts of genetic information on a small glass chip called a probe array. The company can manufacture a number of identical DNA probe arrays on a glass wafer, which is then diced into individual probe arrays. Currently, each probe array manufactured by the company contains from 16,000 to more than 100,000 different DNA probes.

Use of Proceeds
The proceeds from the offering will be used for product development, manufacturing scale-up, research, sales and marketing, capital equipment, working capital and other general corporate purposes.

Last updated: 10/28/96

©1996 IPO Data Systems, Inc. - All rights reserved.